Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2026Expert Opinion on Therapeutic Patents

Myeloperoxidase (MPO) inhibitors: an updated patent review (2020 - present)

View Full Paper
Ask AI
Bookmark
Share

Authors

ZMZhiwei MengDCDan ChenXYXingyu Yao

Discussion

Loading...

Member takes

Overview

This review evaluates MPO inhibitors, focusing on drug discovery challenges and patent literature from 2020 to 2026.

Key Points

  • The aim is to summarize the latest developments in myeloperoxidase inhibitors and their therapeutic potential in inflammatory diseases.
  • Reviewed patent literature from 2020 to 2026 using Espacenet, Google Patents, and SciFinder.
  • Analyzed structural optimization and pharmacological characteristics of MPO inhibitors including small molecules, peptides, and antibodies.
  • Summarized challenges and advancements in MPO drug discovery.
  • Four irreversible MPO inhibitors have progressed to clinical trials but none are available on the market.
  • Current drug discovery efforts center on improving selectivity and pharmacokinetics while developing non-thioxanthine chemotypes.
  • Emerging strategies may involve dual- or multi-target inhibitors to tackle complex inflammatory networks.

Cite This Study

Meng et al. (2026) studied this question.

synapsesocial.com/papers/6a69a2bcc8da07d9defa6973https://doi.org/10.1080/13543776.2026.2710223
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The Role of Neutrophil Extracellular Networks in Cardiovascular Pathology2025 · 15 citations
  2. 2Myeloperoxidase and Cardiovascular Disease2005 · 800 citations
  3. 3Myeloperoxidase inhibitor AZD5904 enhances human sperm function in vitro2020 · 6 citations